Chronic myeloid leukemia (CML) 
Introduction

The clinical presentation of chronic myeloid leukemia (CML) is usually insidious, with most patients presenting in chronic phase. Approximately 10% of patients, however, present in blastic phase (BP) (1). It is deduced that it takes 6 years for patients to become symptomatic from the time of the initial chromosomal translocation (2). It takes 19 months (range, 7 to 24 months) for the white blood cell count to increase from 10,000/μL to 100,000/μL (1). Our two cases resembled Ph-positive acute lymphoid leukemia (ALL) associated with cross-lineage nature, however, the demonstration of BCR-ABL fusion gene in the granulocytes and peripheral mononuclear cells even after the leukemic blasts were decreased in the peripheral blood by chemotherapy, strongly suggested CML-BP with unusually short duration of CML chronic phase. These cases highlight the significance of discriminating Ph-positive ALL from CML-BP since therapeutic strategies differ between the two diseases. CML-BP cases with such characteristics have not been reported to the best of our knowledge.
F i g u r e 1 . B o n e ma r r o w p i c t u r e s o f t h e t wo c a s e s . T h e b o n e ma r r o w s a mp l e s we r e s t a i n e d u s i n g t h e
S S C l o w p o p u l a t i o n ( l e u k e mi c c e l l s ) , a n d a n a l y z e d f o r t h e s u r f a c e e x p r e s s i o n o f e a c h ma r k e r b y f l o w c y t o me t r i c a n a l y s i s . T h e l e u k e mi c c e l l s e xp r e s s e d CD1 3 , CD3 3 a n d CD1 9 , wi t h s u b s t a n t i a l b i p h e n o t y p i c b l a s t p o p u l a t i o n ( CD1
%) . Cy t o p l a s mi c s t a i n i n g o f CD7 9 a wa s p o s i t i v e wh i l e t h a t o f my e l o p e r o x i d a s e ( MP O) wa s n e g a t i v e , i n d i c a t i n g t h e c o mmi t me n t t o B -c e l l l i n e a g e . T h e l e u k e mi c c e l l s a l s o e x p r e s s e d CD3 4 a n d HL A-DR, p o s s i b l y r e f l e c t i n g t h e i mma t u r e c h a r a c t e r i s t i c s .
( d a t a n o t s h o wn ) . An e x t r a s ma l l r e d s i gn a l d e r i v e d f r o m AS S o n c h r o mo s o me 9 wa s l o s t , i n d i c a t i n g t h e d e l e t i o n o f t h i s r e g i o n . T h i s p a tt e r n wa s a l s o f o u n d i n t h e b l a s t c e l l s ( d a t a n o t s h o wn ) . ( b ) Ca s e 2 . B CR-AB L wa s p o s i t i v e i n 7 4 . 0 % o f s e g me n t e d n u c l e a r c e l l s , a n d 8 3 . 0 % o f r o u n d n u c l e a r c e l l s ( d a t a n o t s h o wn ) . A s ma l l f u s i o n s i gn a l d e r i v e d f r o m mi n o r B CR-AB L wa s a l s o s h o wn ( u p p e r a r r o w) .
(a) 
Discussion
The chronic phase of CML generally lasts for 3 to 5 years, followed by an accelerated phase of 3 to 18 months, leading to BP (1) . The present two CML-BP cases showed quite similar clinical courses resembling de novo ALL. They did not show any abnormality in the CBC almost 1 year before the prominent leukocytosis (>100,000/μL) was found. 
The lack of thrombocytopenia and expression of both lymphoid and myeloid markers on the blastic cells prompted us to examine the presence of BCR-ABL transcript. The presence of the BCR-ABL translocation not only in blastic cells, but also in normal granulocytes and mononuclear cells indicated the change in common hematopoietic progenitor cells with multi-lineage differentiation potential, supporting the diagnosis of CML-BP. Neutrophil-FISH is a useful method to demonstrate BCR-ABL-positive leukemic cells in the peripheral blood as real-time quantitative RT-PCR analysis (4). However, it is difficult to strictly distinguish Ph-positive ALL from Ph-positive CML in lymphoid crisis because the significance of BCR-ABL fusion genes in granulocytes of Ph-positive ALL patients has been controversial. It was reported that the Ph-positive ALL cells with cross-lineage nature showed the potential to differentiate into granulocytes in the presence of GM-CSF or G-CSF in a colony assay, indicating that the Ph-positive common progenitors preserved the potential for granulocyte differentiation (5)
.
